Key regions: France, Europe, United Kingdom, Brazil, India
The demand for oncology drugs in Kazakhstan has been on the rise in recent years.
Customer preferences: Kazakhstan has a high incidence rate of cancer, which has led to an increased demand for oncology drugs in the country. Patients and healthcare providers in Kazakhstan prefer drugs that are effective and affordable. As a result, there is a growing demand for generic oncology drugs in the country.
Trends in the market: The oncology drugs market in Kazakhstan is expected to grow in the coming years due to several factors. Firstly, the government of Kazakhstan has implemented healthcare reforms aimed at improving access to healthcare services, including oncology drugs. Secondly, the increasing incidence of cancer in the country is driving the demand for oncology drugs. Thirdly, the rise of medical tourism in Kazakhstan is expected to boost the demand for oncology drugs as more patients seek treatment in the country.
Local special circumstances: Kazakhstan has a unique healthcare system that is a mix of public and private healthcare providers. The government of Kazakhstan is the main provider of healthcare services in the country, but there are also private healthcare providers. The government has implemented healthcare reforms aimed at improving access to healthcare services, including oncology drugs. The government has also implemented measures to promote the local production of drugs, including oncology drugs, in the country.
Underlying macroeconomic factors: Kazakhstan is the largest economy in Central Asia and has a growing middle class. The country has a stable political environment and has implemented economic reforms aimed at attracting foreign investment. The government has also implemented measures to promote local entrepreneurship and innovation. These factors are expected to contribute to the growth of the oncology drugs market in Kazakhstan.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
